Bone Health Technologies (BHT), a leader in developing technologies for improving bone health and preventing bone diseases, announces the appointment of two new board directors: Jeani Delagardelle and Eric Meyer. Onboarding these two expert thought leaders will aid in progressing BHT’s development, research, and overall bandwidth.
“As BHT prepares to launch the Osteoboost solution for the market, we are thrilled to have the board support of industry veterans Eric Meyer and Jeani Delagardelle sharing their expertise from building some of the most iconic health technology products and companies and guiding those companies through their growth phases,” said CEO of Bone Health Technologies, Laura Yecies.
Eric Meyer is a sought-after advisor for emerging-stage companies launching novel consumer medical, health and wellness products. His consulting practice includes clients across various streams, including prescription and OTC products in telehealth, pain management, women’s health, fitness and more. Prior to establishing his consulting practice, Mr. Meyer led Sonicare™’s commercial efforts from launch to achieving the #1 dollar share power toothbrush brand in the U.S., and to Inc. Magazine’s #1 fastest-growing privately-held company. Prior to Sonicare, Mr. Meyer served in senior marketing and sales positions at LifeScan where he launched the One Touch™ blood glucose monitor. During his tenure, LifeScan was successfully sold to Johnson & Johnson. He also served as Chief Commercial Officer for Soovu Labs, as well as CEO of Traffic Gauge. Meyer’s personal mission is to help keep people healthy at home to avoid expensive in-patient care.
“I’m thrilled to be joining Bone Health Technology’s Board of Directors. I look forward to helping the Company deliver novel, drug-free and non-invasive solutions for the millions of people at risk for osteoporosis,” said Eric Meyer.
Jeani Delagardelle is an experienced venture investor and business leader who specializes in founding and developing healthcare technology companies, across all stages of development and therapeutic areas, and guiding them to acquisition or IPO. She is a co-founder and former managing director of New Leaf Venture Partners, a leading life science venture capital firm, spun out of the Sprout Group.
“With no approved treatments for the 52 million patients with osteopenia, there is a unique opportunity to improve patient outcomes while building tremendous business value - I look forward to supporting the company as they work to achieve this mission,” said Jeani Delagardelle.
Adding two experts to its board follows a groundbreaking year for Bone Health Technologies. The Company has had its pivotal trial data selected as a “late-breaking abstract” for the annual meeting of the Endocrine Society, the largest and most prominent endocrinology conference; was named the winner of the 44th Wearable Technologies Innovation World Cup, and secured funding for expansion and continued work towards commercialization of its OsteoBoost technology.
Bone Health Technologies is a Redwood City-based company that applies science and medical expertise to create better health outcomes for women and men at risk of developing osteoporosis and associated bone fractures. Bone Health Technologies is poised to become the new standard of care in treating both osteoporosis and osteopenia (the precursor to osteoporosis). Visit www.bonehealthtech.com for more information.